bioMerieux Aktie
| 101,50EUR | -0,30EUR | -0,29% |
WKN DE: A2DXZH / ISIN: FR0013280286
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Compagnie Merieux Alliance SAS | 58,90 |
| Freefloat | 34,36 |
| Dassault Family | 3,80 |
| Sofina SA (Private Equity) | 1,93 |
| Government Pension Fund - Global (The) | 0,90 |
| bioMérieux SA Employee Stock Ownership Plan | 0,84 |
| ODDO BHF Avenir Europe | 0,65 |
| American Funds EuroPacific Growth Fund | 0,58 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 11 795 | 12 756 | 13 076 | 13 842 | 14 651 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,23 | 0,24 | 0,26 | 0,26 | 0,25 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1 439 | 1 662 | 2 199 | 2 217 | 2 205 |
| Summe Anlagevermögen | 2 343 | 2 266 | 2 418 | 2 970 | 3 054 |
| Summe Aktiva | 3 782 | 3 928 | 4 617 | 5 187 | 5 259 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1 527 | 1 447 | 1 442 | 1 544 | 1 507 |
| Summe Eigenkapital | 2 255 | 2 481 | 3 175 | 3 643 | 3 752 |
| Summe Passiva | 3 782 | 3 928 | 4 617 | 5 187 | 5 259 |
Adresse
| 376, chemin de l'Orme, 69280 Marcy l'Etoile | |
| Telefon | +33 (4) 78-87-20-00 |
| Fax | +33 (4) 78-87-20-90 |
| Internet | http://www.biomerieux.com |
Management
|
Alexandre Mérieux
Executive Chairman |
|
Audrey Dauvet
Executive Vice President-Legal Affairs & Integrity |
|
Aymeric Fichet
Investor Relations Contact |
|
Celine Roger-Dalbert
Executive Vice President-Research & Development |
|
Charles K Cooper
Chief Medical Officer & Executive Vie President |
|
Fanny Letier
Independent Director |
|
Guillaume Bouhours
EVP-Finance, Purchasing & Information Systems |
|
Harold Y. H. Boël
Independent Non-Executive Director |
|
Jean-Luc Bélingard
Non-Independent Director |
|
Jennifer Zinn
Executive Vice President-Clinical Operations |
|
Marie-Hélène Habert-Dassault
Independent Director |
|
Marie-Paule Kieny
Independent Director |
|
Philippe Archinard
Non-Independent Director |
|
Pierre Boulud
Chief Executive Officer |
|
Pierre Charbonnier
Executive Director-Quality & Manufacturing |
|
Sylvain Morgeau
Head-Strategic Planning |
|
Sylvain Orenga
Director |
|
Valérie Leyldé
Executive VP-Human Resources & Communication |
|
Yasha Mitrotti
Executive Director-Industrial Microbiology |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
